[go: up one dir, main page]

NO990471L - Pharmaceutical composition of hedgehog proteins and their use - Google Patents

Pharmaceutical composition of hedgehog proteins and their use

Info

Publication number
NO990471L
NO990471L NO990471A NO990471A NO990471L NO 990471 L NO990471 L NO 990471L NO 990471 A NO990471 A NO 990471A NO 990471 A NO990471 A NO 990471A NO 990471 L NO990471 L NO 990471L
Authority
NO
Norway
Prior art keywords
carrier
hedgehog protein
pharmaceutical composition
hedgehog
binds
Prior art date
Application number
NO990471A
Other languages
Norwegian (no)
Other versions
NO990471D0 (en
Inventor
Kurt Lang
Apollon Papadimitriou
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of NO990471D0 publication Critical patent/NO990471D0/en
Publication of NO990471L publication Critical patent/NO990471L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Farmasøytisk sammensetning av et pinnsvinprotein,at pinnsvinproteinet er bundet til en hydrofil bærer hvilken er biokompatibel og biodegraderbar hvor bæreren er en polymer som binder pinnsvinproteinet som en negativt ladet. bærer som et resultat av ioniske interaksjoner, ikke denaturerer pinnsvinproteinet når det. binder til bæreren,. inneholder minst 0,1 til 2 negativt ladede. residuer per monomer under nøytrale betingelser, inneholder ladningen i formen av sure grupper, - har en gjennomsnittlige molekylvekten på minst 50.000 Da,. - og ikke inneholder agarose. reversibelt og aktivt frigjør pinnsvinproteiner in vivo fra en bærer på en forsinket måte.Pharmaceutical composition of a hedgehog protein, that the hedgehog protein is bound to a hydrophilic carrier which is biocompatible and biodegradable, where the carrier is a polymer that binds the hedgehog protein as a negatively charged. carrier as a result of ionic interactions, does not denature the hedgehog protein when it. binds to the bearer,. contains at least 0.1 to 2 negatively charged. residues per monomer under neutral conditions, contains the charge in the form of acid groups, - has an average molecular weight of at least 50,000 Da,. - and does not contain agarose. reversibly and actively release hedgehog proteins in vivo from a carrier in a delayed manner.

NO990471A 1998-02-04 1999-02-01 Pharmaceutical composition of hedgehog proteins and their use NO990471L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98101893 1998-02-04
EP98104416 1998-03-12

Publications (2)

Publication Number Publication Date
NO990471D0 NO990471D0 (en) 1999-02-01
NO990471L true NO990471L (en) 1999-08-05

Family

ID=26149005

Family Applications (1)

Application Number Title Priority Date Filing Date
NO990471A NO990471L (en) 1998-02-04 1999-02-01 Pharmaceutical composition of hedgehog proteins and their use

Country Status (14)

Country Link
JP (1) JP3092706B2 (en)
KR (2) KR19990072406A (en)
CN (1) CN1228994A (en)
AT (1) ATE331533T1 (en)
AU (1) AU713568B2 (en)
CA (1) CA2260423C (en)
CZ (1) CZ33799A3 (en)
DE (1) DE69932113T2 (en)
HU (1) HUP9900251A3 (en)
IL (1) IL128329A (en)
MA (1) MA26602A1 (en)
NO (1) NO990471L (en)
NZ (1) NZ334065A (en)
SG (1) SG66504A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW570805B (en) 1998-09-01 2004-01-11 Hoffmann La Roche Water-soluble pharmaceutical composition in an ionic complex
KR100452752B1 (en) * 2000-04-18 2004-10-12 주식회사 펩트론 Preparation Method of sustained release dosage forms of protein drugs and the drugs prepared by that method
KR101705323B1 (en) * 2010-03-23 2017-02-13 코웨이 주식회사 Water purifier of reverse osmosis type
KR102176832B1 (en) * 2017-11-29 2020-11-10 주식회사 파이안바이오테크놀로지 A microparticle comprising hedgehog protein and biocompatible material and a composition for preventing or treating hair loss comprising the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866165A (en) 1997-01-15 1999-02-02 Orquest, Inc. Collagen-polysaccharide matrix for bone and cartilage repair

Also Published As

Publication number Publication date
NO990471D0 (en) 1999-02-01
IL128329A (en) 2005-08-31
DE69932113T2 (en) 2007-01-25
HUP9900251A2 (en) 1999-09-28
HU9900251D0 (en) 1999-03-29
HUP9900251A3 (en) 2001-01-29
CA2260423A1 (en) 1999-08-04
CA2260423C (en) 2006-06-20
CZ33799A3 (en) 1999-08-11
KR19990072406A (en) 1999-09-27
DE69932113D1 (en) 2006-08-10
AU713568B2 (en) 1999-12-02
SG66504A1 (en) 2000-07-18
KR100311565B1 (en) 2001-11-02
JP3092706B2 (en) 2000-09-25
CN1228994A (en) 1999-09-22
NZ334065A (en) 2000-06-23
MA26602A1 (en) 2004-12-20
KR19990072423A (en) 1999-09-27
IL128329A0 (en) 2000-01-31
ATE331533T1 (en) 2006-07-15
AU1542699A (en) 1999-08-26
JP2000119193A (en) 2000-04-25

Similar Documents

Publication Publication Date Title
Chandel et al. Self-assembly of partially alkylated dextran-graft-poly [(2-dimethylamino) ethyl methacrylate] copolymer facilitating hydrophobic/hydrophilic drug delivery and improving conetwork hydrogel properties
AU3438199A (en) Controlled release of growth factors from heparin containing matrices
AU9036598A (en) Methods and compositions to prevent formation of adhesions in biological tissues
Abbah et al. In vivo bioactivity of rhBMP-2 delivered with novel polyelectrolyte complexation shells assembled on an alginate microbead core template
CA2291074A1 (en) Composition and method for enhancing transport across biological membranes
EP0894825A4 (en) DIENE POLYMER COMPOSITION, PROCESS FOR PREPARING THE SAME, AND RUBBER COMPOSITION CONTAINING THE FIRST COMPOSITION
CA2239775A1 (en) Crosslinked polymer compositions and methods for their use
JP2003525916A5 (en)
Reed et al. Biological and mechanical characterization of chitosan‐alginate scaffolds for growth factor delivery and chondrogenesis
WO2000015231A8 (en) Adenosine a3 receptor modulators
FR2746035B1 (en) COMPOSITE GEL MICROPARTICLES LIKELY TO BE USED AS VECTOR (S) OF ACTIVE INGREDIENT (S), ONE OF THEIR PREPARATION METHODS AND THEIR APPLICATIONS
BR9812469A (en) Plasma protein containing pharmaceutical compositions
WO2003068144A3 (en) Cytotoxic agents
WO2003084481A3 (en) Biological affinity based delivery systems
WO1998022097A3 (en) Controlled release matrix composition using polar polymer or monomer and poly(acrylic acid) blend
CA2286900A1 (en) Methods for actively binding heparin to cross-linked biological tissues
BR0011554A (en) Compositions and methods for using polymeric foam intensifiers
ATE482689T1 (en) BLOCK COPOLYMER MICELLAR COMPOSITION WITH IMPROVED DRUG LOADING CAPACITY AND SUSTAINED RELEASE
NO990471L (en) Pharmaceutical composition of hedgehog proteins and their use
WO2000018801A3 (en) Ncam binding compounds
AU8067198A (en) Compositions for delivery of biological agents and methods for the preparation thereof
BR9812099A (en) Formulations for filling polyoxyalkylene glycol gelatin capsule comprising cross-linked carboxylic copolymers
Kinnari et al. New method for coating tympanostomy tubes to prevent tube occlusions
WO1990007321A3 (en) Lymphocyte receptor homing sequences and their uses
AR014530A1 (en) PHARMACEUTICAL COMPOSITION OF PROTEINS '' ERIZO '' AND A PROCEDURE FOR THEIR PRODUCTION